Clinical Signs and Activity Limitations Associated With Dural Ectasia in Patients With Marfan Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-02-11

Study Completion Date

2022-09-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary outcome is to compare the frequency and clinical features of spinal symptoms between Marfan patients with dural ectasia (cases) and those without (controls).

1. / Frequency of orthostatic headaches
2. / Frequency of low back pain due to orthostasis
3. / Frequency of low back pain during Vasalva maneuvers
4. / Frequency of lumbar claudication
5. / Frequency of root claudication

Secondary outcomes are to compare activity limitations, quality of life and intensity of low back and radicular pain between Marfan patients with dural sac ectasia (cases) and those without (controls).

1. / Average intensity of back pain measured on a self-administered digital scale (0 = no pain and 100 = maximum pain)
2. / Average intensity of radicular pain measured on a self-administered digital scale (0 = no pain and 100 = maximum pain)
3. / Activity limitations specific to the lumbar spine measured using the self-administered Oswestry Disability Index questionnaire (ODI, 0 = no limitations and 100 = maximum limitations)
4. / Physical component of quality of life measured using the physical component of the self-administered questionnaire 12-Item Short Form Health Survey (SF-12, 9.95 = worst quality of life imaginable, 70.02 = worst quality of life imaginable )
5. / Mental component of the quality of life measured using the mental component of the SF-12 self-administered questionnaire (5.89 = worst quality of life imaginable, 71.97 = worst quality of life imaginable)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect on the Quality of Life of a Therapeutic Education Program in Patients With Marfan Syndrome

NCT04731493

Marfan Syndrome

UNKNOWN

A Magnetic Resonance Imaging Study of Patients With Cervical Spondylosis

NCT01243684

Cervical Spondylosis

COMPLETED NA

Marfan Syndrome (MFS) and Facial Dysmorphism: Non-invasive 3D Assessment

NCT05702476

Rare Diseases Marfan Syndrome

RECRUITING

Prospective Radiographic and Clinical Evaluation of Surgical Treatment for Cervical Deformity

NCT01588054

Cervical Deformity Kyphosis Scoliosis

COMPLETED

The Use of DXA in Scoliosis

NCT06512038

Scoliosis Idiopathic

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Marfan's disease is a rare condition. Clinical phenotypes are heterogeneous. Among the abnormalities of the spine, dural ectasia is common with a prevalence of 66%. This is a major sign of Ghent's diagnostic criteria. To our knowledge, the clinical and functional signs associated with dural sac ectasia have never been described with precision. Only a few uncontrolled case series have been published. This is the case of the study by Foran and colleagues published in the American Journal of Genetics in 2005 which included 22 patients with Marfan disease with dural ectasia questioned about their symptoms and quality of life. We hypothesize the existence of a clinical and functional spinal phenotype specific to dural ectasia in patients with Marfan disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Marfan Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Case group

Marfan disease according to Ghent criteria revised in 2010 with dural ectasia Patients followed at the CNMR in Bichat Adults ≥18 years old and ≤ 55 years old (to limit the incidence of degenerative lumbar pathologies) No history of lumbar surgery \<1 year and without specific pathologies of the spine (tumor, infection, trauma, fracture, inflammatory rheumatism)

Questionnaire

Intervention Type OTHER

Questionnaire

Control group

Marfan disease according to Ghent criteria revised in 2010 without dural ectasia Patients followed at the CNMR in Bichat Adults ≥18 years old and ≤ 55 years old (to limit the incidence of degenerative lumbar pathologies) No history of lumbar surgery \<1 year and without specific pathologies of the spine (tumor, infection, trauma, fracture, inflammatory rheumatism)

Questionnaire

Intervention Type OTHER

Questionnaire

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaire

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Marfan disease according to the Ghent criteria revised in 2010
* Patients followed at the CNMR in Bichat
* Adults ≥18 years old and ≤ 55 years old (to limit the incidence of degenerative lumbar pathologies)
* Patient not opposing the research
* Mastery of the French language

Exclusion Criteria

* History of lumbar surgery \<1 year
* Specific pathologies of the spine (tumor, infection, trauma, fracture, inflammatory rheumatism)
* Inability to write, read or speak French
* Cognitive or behavioral problems making assessment impossible
* Patients receiving AME
* Patients under tutorship or curatorship

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No